BACKGROUND: To investigate the cumulative probability of developing prostate cancer according to prostate-specific antigen (PSA) velocity (PSAV) from first-to second-round PSA-based population screening in men with low baseline serum PSA levels. PATIENTS AND METHODS: A total of 11,913 men aged between 54 and 69 years with baseline PSA levels of ≤2.0 ng/ml at the first population screening and who underwent population screening at least twice, were enrolled. The cumulative probability of developing prostate cancer according to age, baseline PSA and PSAV was investigated. The clinicopathological features of screen-detected cancer were also investigated. RESULTS: Out of the 11,913 men, 110 (0.92%) were pathologically diagnosed with prostate cancer during the observation period. The cumulative probability of developing prostate cancer in all participants after 5 and 10 years was 0.64% and 1.79%, respectively. Univariate and multivariate analyses determined that baseline PSA levels and PSAVs were significant predictors of developing cancer and the hazard ratio increased with increasing baseline PSA levels and PSAVs. The optimal PSAV cut-off levels for prostate cancer development were 0.069, 0.106 and 0.285 for the baseline PSA ranges of 0.0-1.0, 1.1-1.5 and 1.6-2.0 ng/ml, respectively. There were no significant differences in baseline PSA levels and PSAVs according to the clinical characteristics of the screen-detected prostate cancer patients. CONCLUSION: The present study demonstrated that serum PSA levels at second round screening were a strong predictor of cancer development in men with baseline PSA levels≤2.0 ng/ml at the first population screening. Copyright
BACKGROUND: To investigate the cumulative probability of developing prostate cancer according to prostate-specific antigen (PSA) velocity (PSAV) from first-to second-round PSA-based population screening in men with low baseline serum PSA levels. PATIENTS AND METHODS: A total of 11,913 men aged between 54 and 69 years with baseline PSA levels of ≤2.0 ng/ml at the first population screening and who underwent population screening at least twice, were enrolled. The cumulative probability of developing prostate cancer according to age, baseline PSA and PSAV was investigated. The clinicopathological features of screen-detected cancer were also investigated. RESULTS: Out of the 11,913 men, 110 (0.92%) were pathologically diagnosed with prostate cancer during the observation period. The cumulative probability of developing prostate cancer in all participants after 5 and 10 years was 0.64% and 1.79%, respectively. Univariate and multivariate analyses determined that baseline PSA levels and PSAVs were significant predictors of developing cancer and the hazard ratio increased with increasing baseline PSA levels and PSAVs. The optimal PSAV cut-off levels for prostate cancer development were 0.069, 0.106 and 0.285 for the baseline PSA ranges of 0.0-1.0, 1.1-1.5 and 1.6-2.0 ng/ml, respectively. There were no significant differences in baseline PSA levels and PSAVs according to the clinical characteristics of the screen-detected prostate cancerpatients. CONCLUSION: The present study demonstrated that serum PSA levels at second round screening were a strong predictor of cancer development in men with baseline PSA levels≤2.0 ng/ml at the first population screening. Copyright
Authors: Christos Mikropoulos; Christina G Hutten Selkirk; Sibel Saya; Elizabeth Bancroft; Emily Vertosick; Tokhir Dadaev; Charles Brendler; Elizabeth Page; Alexander Dias; D Gareth Evans; Jeanette Rothwell; Lovise Maehle; Karol Axcrona; Kate Richardson; Diana Eccles; Thomas Jensen; Palle J Osther; Christi J van Asperen; Hans Vasen; Lambertus A Kiemeney; Janneke Ringelberg; Cezary Cybulski; Dominika Wokolorczyk; Rachel Hart; Wayne Glover; Jimmy Lam; Louise Taylor; Monica Salinas; Lidia Feliubadaló; Rogier Oldenburg; Ruben Cremers; Gerald Verhaegh; Wendy A van Zelst-Stams; Jan C Oosterwijk; Jackie Cook; Derek J Rosario; Saundra S Buys; Tom Conner; Susan Domchek; Jacquelyn Powers; Margreet Gem Ausems; Manuel R Teixeira; Sofia Maia; Louise Izatt; Rita Schmutzler; Kerstin Rhiem; William D Foulkes; Talia Boshari; Rosemarie Davidson; Marielle Ruijs; Apollonia Tjm Helderman-van den Enden; Lesley Andrews; Lisa Walker; Katie Snape; Alex Henderson; Irene Jobson; Geoffrey J Lindeman; Annelie Liljegren; Marion Harris; Muriel A Adank; Judy Kirk; Amy Taylor; Rachel Susman; Rakefet Chen-Shtoyerman; Nicholas Pachter; Allan Spigelman; Lucy Side; Janez Zgajnar; Josefina Mora; Carole Brewer; Neus Gadea; Angela F Brady; David Gallagher; Theo van Os; Alan Donaldson; Vigdis Stefansdottir; Julian Barwell; Paul A James; Declan Murphy; Eitan Friedman; Nicola Nicolai; Lynn Greenhalgh; Elias Obeid; Vedang Murthy; Lucia Copakova; John McGrath; Soo-Hwang Teo; Sara Strom; Karin Kast; Daniel A Leongamornlert; Anthony Chamberlain; Jenny Pope; Anna C Newlin; Neil Aaronson; Audrey Ardern-Jones; Chris Bangma; Elena Castro; David Dearnaley; Jorunn Eyfjord; Alison Falconer; Christopher S Foster; Henrik Gronberg; Freddie C Hamdy; Oskar Johannsson; Vincent Khoo; Jan Lubinski; Eli Marie Grindedal; Joanne McKinley; Kylie Shackleton; Anita V Mitra; Clare Moynihan; Gad Rennert; Mohnish Suri; Karen Tricker; Sue Moss; Zsofia Kote-Jarai; Andrew Vickers; Hans Lilja; Brian T Helfand; Rosalind A Eeles Journal: Br J Cancer Date: 2018-01-04 Impact factor: 7.640